Evidence map›Paper›PMID 33508020›Full record

ArticlePLoS pathogens2021

Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease.

Wei Wang, Duo Peng, Rodrigo P Baptista, Yiran Li, Jessica C Kissinger, Rick L Tarleton

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cloning-Free Genome Editing by CRISPR/T7RNAP/Cas9 in Trypanosoma cruzi.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  8. An Algorithm for Annotation of Trypanosoma cruzi MASP Sequences.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. ClinicalbioRxiv : the preprint server for biology · 2025
    Article
  15. Genomic Organization of Trypanosoma cruzi tRNA Genes.Genome biology and evolution · 2025
    Article
  16. Hidden origami inmBio · 2025
    Article
  17. Immunogenicity ofPathogens (Basel, Switzerland) · 2025
    Article
  18. mSphere of Influence:mSphere · 2025
    Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wei WangCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0001-7111-4687
Duo PengCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0001-7540-8623
Rodrigo P BaptistaCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-1806-8260
Yiran LiInstitute of Bioinformatics, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-6339-5324
Jessica C KissingerCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-6413-1101
Rick L TarletonCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-9589-5243
University of Georgia · US

Funding

Mechanisms of persistence in Trypanosoma cruzi infectionR01AI124692 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2016 to 2020
$1.9M
Generation of reference genomes for Trypanosoma cruzi using PacBio sequencingR03AI124228 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2016 to 2017
$150k
NIAID NIH HHS R01 AI124692NIAID NIH HHS R03 AI124228
6 · The paper itself

Abstract

The protozoan Trypanosoma cruzi almost invariably establishes life-long infections in humans and other mammals, despite the development of potent host immune responses that constrain parasite numbers. The consistent, decades-long persistence of T. cruzi in human hosts arises at least in part from the remarkable level of genetic diversity in multiple families of genes encoding the primary target antigens of anti-parasite immune responses. However, the highly repetitive nature of the genome-largely a result of these same extensive families of genes-have prevented a full understanding of the extent of gene diversity and its maintenance in T. cruzi. In this study, we have combined long-read sequencing and proximity ligation mapping to generate very high-quality assemblies of two T. cruzi strains representing the apparent ancestral lineages of the species. These assemblies reveal not only the full repertoire of the members of large gene families in the two strains, demonstrating extreme diversity within and between isolates, but also provide evidence of the processes that generate and maintain that diversity, including extensive gene amplification, dispersion of copies throughout the genome and diversification via recombination and in situ mutations. Gene amplification events also yield significant copy number variations in a substantial number of genes presumably not required for or involved in immune evasion, thus forming a second level of strain-dependent variation in this species. The extreme genome flexibility evident in T. cruzi also appears to create unique challenges with respect to preserving core genome functions and gene expression that sets this species apart from related kinetoplastids.

Indexed as

DNA Copy Number VariationsChagas DiseaseEvolution, MolecularGenetic VariationGenome, ProtozoanHumansTrypanosoma cruzi

Identifiers

PMID33508020
PMCPMC7872254
OpenAlexW3125532839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.